home / stock / sls / sls news

SLS News and Press, SELLAS Life Sciences Group Inc. From 03/15/24

Stock Information
Company Name: SELLAS Life Sciences Group Inc.
Stock Symbol: SLS
Market: NASDAQ
Website: sellaslifesciences.com
Menu
SLS SLS Quote SLS Short SLS News SLS Articles SLS Message Board
Get SLS Alerts

News, Short Squeeze, Breakout and More Instantly...
SLS - Geron, Graphite Bio, Immuneering among healthcare movers

2024-03-15 10:00:13 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
SLS - US Companies Moving the Markets, Morning edition
Fri, Mar 15, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Grab Holdings Limited (GRAB) fell 0.2% to $3.235 on volume of 103,635,000 shares Better Therapeutics Inc. (BTTX) rose 108.6% to $0.073 on volume of 98,804,254 shares Verb Technology Company Inc. (VERB) rose 156.3% to $0.3639 on volume...

SLS - SELLAS Life Sciences looks to raise $20M in a direct offering

2024-03-15 09:18:40 ET More on SELLAS Life Sciences Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Sellas Life Sciences gains after leukemia therapy gets FDA fast track status Read the full article on Seeking Alpha For furthe...

SLS - SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today...
SLS - Solaris Provides Disclosure Clarifications

VANCOUVER, British Columbia, March 13, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc . (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is issuing the following news release as a result of a continuous disclosure review by the British Columbia Securities Comm...

SLS - SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today...

SLS - SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of eight months and one year survival at the latest assessment - - First time achievemen...
SLS - Solaris Announces Cooperation Agreement with Interprovincial Federation of Shuar Centers and the Alliance for Entrepreneurship and Innovation of Ecuador

VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to announce a trilateral cooperation agreement with the Interprovincial Federation of Shuar Centers (“FICS...

SLS - SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announce...

SLS - SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...
Previous 10 Next 10